These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 31347977)

  • 1. Health Care Effect of Disease-Modifying Antirheumatic Drug Use on Patients with Rheumatoid Arthritis.
    Boytsov NN; Bhattacharya R; Saverno K; Dixon L; Abbott PL; Zhang X; Gaich CL; Nair R
    J Manag Care Spec Pharm; 2019 Aug; 25(8):879-887. PubMed ID: 31347977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.
    Strand V; Tundia N; Song Y; Macaulay D; Fuldeore M
    J Manag Care Spec Pharm; 2018 Apr; 24(4):344-352. PubMed ID: 29578852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
    Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
    J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.
    Betts KA; Griffith J; Ganguli A; Li N; Douglas K; Wu EQ
    Clin Ther; 2016 May; 38(5):1205-16. PubMed ID: 27045991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Economic Burden of ACPA-Positive Status Among Patients with Rheumatoid Arthritis.
    Shafrin J; Tebeka MG; Price K; Patel C; Michaud K
    J Manag Care Spec Pharm; 2018 Jan; 24(1):4-11. PubMed ID: 29290168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
    Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
    Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Evaluation of Anticyclic Citrullinated Peptide Positivity in Rheumatoid Arthritis.
    An J; Bider-Canfield Z; Kang J; Alemao E; Connolly SE; Lin AT; Cheetham TC
    J Manag Care Spec Pharm; 2019 Apr; 25(4):469-477. PubMed ID: 30917075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.
    Angelici L; Addis A; Agabiti N; Kirchmayer U; Davoli M; Belleudi V
    Medicine (Baltimore); 2021 May; 100(19):e25943. PubMed ID: 34106665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease-modifying antirheumatic drug initiation among patients newly diagnosed with rheumatoid arthritis.
    Bonafede M; Johnson BH; Shah N; Harrison DJ; Tang D; Stolshek BS
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP279-SP285. PubMed ID: 30020740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Medical Utilization and Cost Outcomes in Oral Versus Injectable Immunotherapy Users with Chronic Inflammatory Joint and Skin Diseases.
    Bhattacharya R; Herren K; Poonawalla I; Bunniran S; Bloomfield A; Schwab P
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1246-1256. PubMed ID: 32996385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with use of disease modifying agents for rheumatoid arthritis in the National Hospital and Ambulatory Medical Care Survey.
    Gaitonde P; Bozzi LM; Shaya FT
    Semin Arthritis Rheum; 2018 Apr; 47(5):649-653. PubMed ID: 29153870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Geographic Variation in the Quality and Cost of Care for Patients with Rheumatoid Arthritis.
    Shafrin J; Ganguli A; Gonzalez YS; Shim JJ; Seabury SA
    J Manag Care Spec Pharm; 2016 Dec; 22(12):1472-1481. PubMed ID: 27882832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Contribution of leflunomide to the cost effectiveness of sequential DMARD therapy of rheumatoid arthritis in Germany].
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Z Rheumatol; 2004 Feb; 63(1):59-75. PubMed ID: 14991279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rates, factors, reasons, and economic impact associated with switching in rheumatoid arthritis patients newly initiated on biologic disease modifying anti-rheumatic drugs in an integrated healthcare system.
    Rashid N; Lin AT; Aranda G; Lin KJ; Guerrero VN; Nadkarni A; Patel C
    J Med Econ; 2016 Jun; 19(6):568-75. PubMed ID: 26766553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data.
    Steffen A; Holstiege J; Klimke K; Akmatov MK; Bätzing J
    Rheumatol Int; 2018 Nov; 38(11):2111-2120. PubMed ID: 30306254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refining a Claims-based Algorithm to Estimate Biologic Medication Effectiveness and Cost per Effectively Treated Patient with Rheumatoid Arthritis.
    Popp RA; Rascati K; Davis M; Patel U
    Pharmacotherapy; 2018 Feb; 38(2):172-180. PubMed ID: 29197108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.